期刊
JCO PRECISION ONCOLOGY
卷 6, 期 -, 页码 -出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/PO.21.00547
关键词
-
类别
资金
- National Institutes of Health [T32 CA009599]
- MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer
- MD Anderson Cancer Center Support Grant [P30 CA016672]
- NIH/NCI [1R01 CA262469-01]
- CPRIT [RP200287]
- NIH Clinical Translational Science Award [1UL1TR003167]
This study conducted a comprehensive analysis of KRAS(G12C) mutations in different types of cancer through liquid biopsy. The results showed that KRAS(G12C) mutations were detected in various cancers, with the highest detection rate in lung cancer.
PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRAS(G12C) mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRAS(G12C) inhibitors. Nevertheless, to date, there have been no large-scale analyses of liquid biopsy that include testing for KRAS(G12C). Here, we performed a comprehensive analysis of KRAS(G12C) mutations in multiple cancer types, as detected by circulating tumor DNA. METHODS We conducted a 5-year retrospective review of KRAS(G12C) mutations in patients with cancer who had undergone Guardant360 testing between July 1, 2014, and June 30, 2019; our study included treatment-naive and previously treated patients with metastatic solid tumors. RESULTS KRAS(G12C) mutations were identified in 2,985 of 80,911 patients (3.7%), across. 40 tumor types. KRAS(G12C) mutations were detected most frequently in patients with nonsquamous non-small-cell lung cancer (NSCLC; 7.5%), NSCLC of all subtypes (6.9%), cancer of unknown primary (4.1%), colorectal cancer (3.5%), squamous NSCLC (2.0%), pulmonary neuroendocrine tumors (1.9%), and pancreatic ductal adenocarcinoma (1.2%) and cholangiocarcinoma (1.2%). KRAS(G12C) mutations were predominantly clonal (clonality. 0.9%) in patients with lung adenocarcinoma, non-NSCLC, cancer of unknown primary, NSCLC, and pancreatic ductal adenocarcinoma, and patients with colorectal cancer and breast cancer had bimodal distribution of clonal and subclonal KRAS(G12C) mutations. CONCLUSION Our study demonstrates the feasibility of using circulating tumor DNA to identify KRAS(G12C) mutations across solid tumors; the highest detection rate was in lung cancer, as previously reported in the literature. (c) 2022 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据